Found 5 results

Name Type of Offering Accepted Date
Vivace Therapeutics, Inc. See All Filings
D 2025-03-12 14:40:09
Amount To Be Raised $34,999,993
Associated Brokers / Dealers N/A
CIK Number 0001630575
Filed Document 0001630575-25-000001
Exclusions or Exemptions 506b
Accepted Date 2025-03-12 14:40:09
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business CALIFORNIA
Revenue or Assets Decline to Disclose
Type of Security Equity
Vivace Therapeutics, Inc. See All Filings
D 2015-01-20
Amount To Be Raised $15,050,000
Associated Brokers / Dealers N/A
CIK Number 0001630575
Filed Document 0001630575-15-000001
Exclusions or Exemptions 506b
Accepted Date 2015-01-20
Type of Offering D
Industry Pharmaceuticals
Offering Tier N/A
Principal Place of Business CALIFORNIA
Revenue or Assets Decline to Disclose
Type of Security Equity
Vivace Therapeutics, Inc. See All Filings
D 2020-12-22 18:17:36
Amount To Be Raised $29,999,993
Associated Brokers / Dealers N/A
CIK Number 0001630575
Filed Document 0001630575-20-000003
Exclusions or Exemptions 506b
Accepted Date 2020-12-22 18:17:36
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business CALIFORNIA
Revenue or Assets Decline to Disclose
Type of Security Equity
Vivace Therapeutics, Inc. See All Filings
D 2017-05-18 11:35:40
Amount To Be Raised $24,999,998
Associated Brokers / Dealers N/A
CIK Number 0001630575
Filed Document 0001630575-17-000003
Exclusions or Exemptions 506b
Accepted Date 2017-05-18 11:35:40
Type of Offering D
Industry Biotechnology
Offering Tier N/A
Principal Place of Business CALIFORNIA
Revenue or Assets Decline to Disclose
Type of Security Equity
Vivace Therapeutics, Inc. See All Filings
D/A 2018-05-01 16:42:45
Amount To Be Raised $24,999,998
Associated Brokers / Dealers N/A
CIK Number 0001630575
Filed Document 0001630575-18-000001
Exclusions or Exemptions 506b
Accepted Date 2018-05-01 16:42:45
Type of Offering D/A
Industry Biotechnology
Offering Tier N/A
Principal Place of Business CALIFORNIA
Revenue or Assets Decline to Disclose
Type of Security Equity